Galena Biopharma, Inc. (GALE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Date: November 18, 2014
Pages: 63
Price:
US$ 250.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: GDD170A45F6EN
Leaflet:

Download PDF Leaflet

Galena Biopharma, Inc. (GALE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Summary

Galena Biopharma, Inc. (Galena) is a biotechnology company. The company discovers, develops and commercializes therapies for the treatment of unmet medical needs, and advance care. Its products include Abstral, NeuVax, NeuVax Herceptin, and folate binding protein. The company provides NeuVax and NeuVax Hercepti for the treatment of breast cancer and folate binding protein for the treatment of endometrial and ovarian cancer. Galena’s Abstral is a sublingual tablets for the management of breakthrough pain in cancer patients of 18 years of age. It partners with academia, small companies, and large multinationals. Galena is headquartered in Lake Portland, Oregon, the US.

Galena Biopharma, Inc. (GALE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope
  • Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
  • Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
  • Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
  • Key Competitors - A list of the key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.
Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
  • The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
  • The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
  • Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
  • Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
  • Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company.
Galena Biopharma, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Galena Biopharma, Inc., Pharmaceuticals & Healthcare Deals By Type, 2008 to YTD 2014
Galena Biopharma, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014
Galena Biopharma, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2008 to YTD 2014
Galena Biopharma, Inc., Medical Devices Deals, 2008 to YTD 2014
Galena Biopharma, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2008 to YTD 2014
Galena Biopharma, Inc., Pharmaceuticals & Healthcare, Deal Details
Asset Purchase
Galena Biopharma Acquires Abstral Sublingual Tablets From Orexo For US$15 Million
RXi Pharma To Acquire RNAi-Related Assets From Opko Health
RXi Pharma Acquires RNAi Therapeutics Technology From Advirna
Partnerships
RXi Pharma Enters Into Licensing Agreement With The Henry M. Jackson Foundation For NeuVax
RXi Pharma And Ethicor Enter Into Distribution Agreement For RXI-109
Galena Biopharma Enters Into Commercialization Agreement With Teva Pharma For NeuVax
Galena Biopharma Enters Into Co-Development Agreement With The Henry M. Jackson Foundation And Genentech
RXi Pharma Enters Into Collaboration With Eyegate Pharma
Royal Philips Electronics Enters Into Research Agreement With RXi Pharma
RXi Pharma Enters Into Research Agreement With Mirna Therapeutics
RXi Pharma Enters Into Research Agreement With miRagen Therapeutics
RXi Pharma Enters Into Research Agreement With TransDerm
RXi Pharma Enters Into Co-Development Agreement With The UMMS
University of Massachusetts Enters Into An Agreement With RXi Pharma
Licensing Agreements
Monosol Rx Enters into Licensing Agreement with Galena Biopharma for Zuplenz
Galena Biopharma Enters Into Licensing Agreement With Dr. Reddy's Labs For NeuVax
RXi Pharma Enters Into Licensing Agreement With The University Of Texas MD Anderson And HJF
RXi Pharma Enters Into Licensing Agreement With Advirna
University of Massachusetts Medical School Expands Licensing Agreement With RXi Pharma For Oral Administration Of RNAi Therapeutics
Apthera Enters Into Licensing Agreement With Kwang Dong Pharma
RXi Pharma Enters Into Licensing Agreement With The University of Massachusetts Medical School
Equity Offering
RXi Pharma Completes First Tranche Of Private Placement Of Shares For US$2 Million
Galena Biopharma Completes Underwriters Exercise Of Full Over-Allotment Option Of Public Offering Of Units For US$40 Million
RXi Pharma Completes Private Placement Of Shares For US$16 Million
Galena Biopharma Completes Public Offering Of Units For US$24 Million
Galena Biopharma Completes Public Offering Of Common Stock For US$14.5 Million
Galena Biopharma Completes Private Placement Of Shares For US$0.4 Million
RXi Pharma Completes Public Offering Of US$12 Million
RXi Pharma Completes Public Offering For US$8.1 Million
RXi Pharma Completes Private Placement Of US$16.2 Million
RXi Pharma Completes Public Offering Of US$8 Million
RXi Pharma Completes Private Placement Of US$9 Million
Acquisition
Galena Biopharma Acquires Mills Pharma For US$4.6 Million
RXi Pharma Completes Acquisition Of Apthera
CytRx Sells Remaining 17% Stake In RXi Pharma For US$7 Million
Galena Biopharma, Inc. - Key Competitors
Key Employees
Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Galena Biopharma, Inc., Pharmaceuticals & Healthcare, Key Facts, 2013
Galena Biopharma, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Galena Biopharma, Inc., Pharmaceuticals & Healthcare Deals By Type, 2008 to YTD 2014
Galena Biopharma, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014
Galena Biopharma, Inc., Deals By Therapy Area, 2008 to YTD 2014
Galena Biopharma, Inc., Medical Devices Deals, 2008 to YTD 2014
Galena Biopharma, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2008 to YTD 2014
Galena Biopharma Acquires Abstral Sublingual Tablets From Orexo For US$15 Million
RXi Pharma To Acquire RNAi-Related Assets From Opko Health
RXi Pharma Acquires RNAi Therapeutics Technology From Advirna
RXi Pharma Enters Into Licensing Agreement With The Henry M. Jackson Foundation For NeuVax
RXi Pharma And Ethicor Enter Into Distribution Agreement For RXI-109
Galena Biopharma Enters Into Commercialization Agreement With Teva Pharma For NeuVax
Galena Biopharma Enters Into Co-Development Agreement With The Henry M. Jackson Foundation And Genentech
RXi Pharma Enters Into Collaboration With Eyegate Pharma
Royal Philips Electronics Enters Into Research Agreement With RXi Pharma
RXi Pharma Enters Into Research Agreement With Mirna Therapeutics
RXi Pharma Enters Into Research Agreement With miRagen Therapeutics
RXi Pharma Enters Into Research Agreement With TransDerm
RXi Pharma Enters Into Co-Development Agreement With The UMMS
University of Massachusetts Enters Into An Agreement With RXi Pharma
Monosol Rx Enters into Licensing Agreement with Galena Biopharma for Zuplenz
Galena Biopharma Enters Into Licensing Agreement With Dr. Reddy's Labs For NeuVax
RXi Pharma Enters Into Licensing Agreement With The University Of Texas MD Anderson And HJF
RXi Pharma Enters Into Licensing Agreement With Advirna
University of Massachusetts Medical School Expands Licensing Agreement With RXi Pharma For Oral Administration Of RNAi Therapeutics
Apthera Enters Into Licensing Agreement With Kwang Dong Pharma
RXi Pharma Enters Into Licensing Agreement With The University of Massachusetts Medical School
RXi Pharma Completes First Tranche Of Private Placement Of Shares For US$2 Million
Galena Biopharma Completes Underwriters Exercise Of Full Over-Allotment Option Of Public Offering Of Units For US$40 Million
RXi Pharma Completes Private Placement Of Shares For US$16 Million
Galena Biopharma Completes Public Offering Of Units For US$24 Million
Galena Biopharma Completes Public Offering Of Common Stock For US$14.5 Million
Galena Biopharma Completes Private Placement Of Shares For US$0.4 Million
RXi Pharma Completes Public Offering Of US$12 Million
RXi Pharma Completes Public Offering For US$8.1 Million
RXi Pharma Completes Private Placement Of US$16.2 Million
RXi Pharma Completes Public Offering Of US$8 Million
RXi Pharma Completes Private Placement Of US$9 Million
Galena Biopharma Acquires Mills Pharma For US$4.6 Million
RXi Pharma Completes Acquisition Of Apthera
CytRx Sells Remaining 17% Stake In RXi Pharma For US$7 Million
Galena Biopharma, Inc., Key Competitors
Galena Biopharma, Inc., Key Employees
Galena Biopharma, Inc., Subsidiaries

LIST OF FIGURES

Galena Biopharma, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014
Galena Biopharma, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Galena Biopharma, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014
Galena Biopharma, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2008 to YTD 2014
Galena Biopharma, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Galena Biopharma, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014
Galena Biopharma, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014
Galena Biopharma, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2008 to YTD 2014
Galena Biopharma, Inc., Medical Devices Deals, 2008 to YTD 2014
Skip to top


Ask Your Question

Galena Biopharma, Inc. (GALE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: